<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546676</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A_4018</org_study_id>
    <nct_id>NCT00546676</nct_id>
  </id_info>
  <brief_title>Ketek in CAP / AECB in Ambulatory Adult Patients</brief_title>
  <official_title>A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To determine the clinical effectiveness of telithromycin in the treatment of either CAP or
      AECB in a large population of ambulatory adult patients in a community-based setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the clinical effectiveness of telithromycin treatment as determined by the clinical cure rates based on the resolution of infection-related signs and symptoms for CAP and AECB.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate speed of symptom resolution,define the safety of telithromycin,&amp; assess health economic parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">174</enrollment>
  <condition>Community Acquired Pneumonia (CAP)</condition>
  <condition>Acute Exacerbation of Chronic Bronchitis (AECB)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female subjects greater than or equal to 18 years who fulfill the clinical
        diagnostic criteria for outpatient treatment of one of the two following community acquired
        respiratory tract infections (CARTIs):

          -  CAP: a new pulmonary infiltrate confirmed by chest X-ray and at least 3 of the
             following signs or symptoms of infection: fever greater than or equal to 38C, cough,
             chest pain, sputum production, rales, dyspnea, malaise and/or headache; OR

          -  ECB: documented medical history of chronic bronchitis in subjects over the age of 40
             and presenting an FEV1 &lt;80% of the predicted value in the last 36 months and at least
             2 of the following clinical symptoms: increased sputum purulence, increased dyspnea
             and/or increased sputum production.

        Exclusion Criteria:

          -  Subjects with a confirmed cardiogenic syncope, ventricular tachyarrythmia or Torsades
             de Pointes while taking a medicinal product with QT- prolonging potential, such as a
             macrolide or quinolone antibiotic, or other non-antibiotic suspected of prolonging the
             QT interval;

          -  Pregnancy or lactation;

          -  Hypersensitivity to macrolides;

          -  Concomitant treatment with terfenadine, ergot alkaloid derivatives, astemizole or
             pimozide;

          -  Myasthenia gravis;

          -  Antibiotic treatment in the 30 days prior to study entry;

          -  Treatment with any investigational product in the 30 days prior to study entry and/or
             a previous participation in this study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Mississian</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>November 13, 2007</last_update_submitted>
  <last_update_submitted_qc>November 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

